Overview: KRAS Codon 61 Mutation TestIntroduction: The KRAS Codon 61 Mutation Test detects KRAS codon 61 mutations to diagnose colorectal or lung cancer, causing pain or bleeding. Following 2023 NCCN guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected colorectal or lung cancer.
Other Names: KRAS Codon 61 PCR Assay, Colorectal/Lung Cancer Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: KRAS mutation testing began in the 2000s with cancer research. PCR-based methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects KRAS codon 61 mutation to diagnose colorectal or lung cancer, guides treatment, and evaluates patients with pain or bleeding.
Test Parameters: 1. KRAS Codon 61 Mutation
Pretest Condition: No fasting required. Collect tissue, whole blood, or saliva. Report history of pain, bleeding, or cancer symptoms.
Specimen: Tissue (FFPE, 0.5-2 cma³), Whole Blood (EDTA, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document pain, bleeding, weight loss, or family history of colorectal or lung cancer. Include current medications, especially targeted therapies.
Consent: Written consent required, detailing the tests purpose, cancer implications, and risks of biopsy or blood collection.
Procedural Considerations: Uses PCR to detect KRAS codon 61 mutations in tissue, whole blood, or saliva. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for targeted therapy eligibility.
Factors Affecting Result Accuracy: Improper tissue fixation or low DNA yield can affect results. Contamination may reduce specificity.
Clinical Significance: Positive KRAS codon 61 mutation confirms colorectal or lung cancer, guiding anti-EGFR therapy decisions. Negative results may require further mutation testing.
Specialist Consultation: Consult an oncologist for result interpretation and treatment planning.
Additional Supporting Tests: KRAS codon 12/13 PCR, EGFR mutation testing, or PET-CT to confirm colorectal or lung cancer diagnosis.
Test Limitations: Not specific to one cancer type; clinical correlation is needed. Rare mutations may not be detected.
References: NCCN Colorectal Cancer Guidelines, 2023; Journal of Clinical Oncology, Allegra CJ, 2022.
